SCHEDULE: Millennium Management Discloses 5.1% Stake in ALX Oncology

Millennium Management LLC and affiliates have reported a 5.1% beneficial ownership stake in ALX Oncology Holdings Inc., signaling significant institutional interest.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are the reporting persons.
• They collectively beneficially own 2,707,151 shares of ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share.
• This ownership represents 5.1% of the class of securities.
• The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Israel A. Englander.
• The filing date is October 7, 2025, for an event that occurred on October 2, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by a reputable fund like Millennium Management is generally viewed positively as it indicates confidence and potential for increased liquidity, though it is a routine compliance filing.

Positives

• A significant institutional investment by Millennium Management, a prominent hedge fund, in ALX Oncology Holdings Inc.
• The acquisition of a 5.1% stake indicates confidence in the company's prospects from a major financial player.

Risks

• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11. This clarifies the passive nature of their investment.

Future Outlook

NA

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

Millennium Management's investment in ALX Oncology, a biotech firm, aligns with broader trends of institutional investors seeking opportunities in the life sciences sector, particularly in companies with promising pipelines or market positions. Such investments often signal a belief in the long-term growth potential of the company within its specialized industry.

Stakeholder Impact

• Shareholders may view the investment as a positive signal, potentially increasing investor confidence and demand for the stock.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial stake, which is generally a positive signal. However, a Schedule 13G filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. It primarily confirms a change in beneficial ownership. Investors should hold and monitor ALX Oncology's fundamental performance and future announcements.

Keywords

ALX Oncology Holdings Inc., Millennium Management LLC, Israel A. Englander, Schedule 13G, beneficial ownership, common stock, institutional investment, biotech, healthcare